Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
|Articles|February 7, 2022
Pharmacy Clinical Pearl of the Day: Greenstick Fractures
Author(s)Saro Arakelians, PharmD
Greenstick fractures occur most commonly in children because their bones are softer and more flexible than the bones of adults.
Advertisement
Clinical Pearl of the Day: Greenstick Fractures
A greenstick fracture occurs when a bone bends and cracks instead of breaking completely into separate pieces.
Insight:
- Most greenstick fractures occur in children younger than 10 years of age.
- This type of broken bone most commonly occurs in children because their bones are softer and more flexible than the bones of adults.
- Even mild greenstick fractures are usually immobilized in a cast.
- Diagnosis includes physical exam and X-ray to determine the extent of the fracture.
- The physician may provide a splint. Recheck of the arm is needed within 4 to 8 weeks after the fracture to make sure the fracture is completely healed. If not, the provider may suggest the use of a cast.
Sources:
Advertisement
Related to this article
Authors of a pharmacist-directed transitions-of-care study discuss what drives pneumococcal vaccine hesitancy and how pharmacists can build systematic vaccine screening into inpatient workflows.
An MRD-guided strategy incorporating teclistamab-daratumumab intensification produced deep responses in newly diagnosed high-risk multiple myeloma, although infections affected more than three-quarters of treated patients.
Researchers found substantial overlap in autonomic symptoms, orthostatic tachycardia, and functional impairment between long COVID and POTS.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
Fixed-duration KRd slowed progression in high-risk smoldering myeloma, but high rates of severe toxicity temper enthusiasm.
A review of 69 studies finds influenza vaccines continue to reduce hospitalization and death, with no new safety concerns.
The FDA approved lirafugratinib for adults with previously treated, advanced cholangiocarcinoma harboring an FGFR2 fusion or other rearrangement after the REFOCUS trial showed a 46% ORR.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Nearly Two-Thirds of Patients With Long COVID Meet Diagnostic Criteria for POTS
2
After 180 Years, Multiple Myeloma Gets a Definition of Cure
3
Teclistamab-Daratumumab Intensification Achieves 73% MRD-Negative CR Rate in High-Risk Multiple Myeloma
4
Tec-Dara Cuts Death Risk 78% Without Raising Fatal Toxicity
5